大疱性类天疱疮患者的全因死亡率、心血管疾病死亡率和癌症死亡率风险
这项在台湾中部一家三级医疗中心开展的队列研究,纳入2007年1月1日至2017年12月31日皮肤科门诊诊断并治疗的大疱性类天疱疮(BP)患者252例,按年龄、性别和就诊日期4:1匹配无BP对照1008例。BP患者1年、3年、5年心血管疾病(CVD)死亡率均高于对照,校正后CVD死亡风险约为对照的5倍,在无高血压、无CVD史或无既往利尿剂使用患者中风险更高;无既往糖皮质激素使用患者全因死亡风险也高于对照。
要点
- BP患者1年CVD死亡20例(7.9%)vs 对照13例(1.3%),3年28例(11.1%)vs 24例(2.4%),5年31例(12.3%)vs 39例(3.9%)。
- 校正混杂后BP患者1年CVD死亡HR 5.29(95%CI 2.40-11.68),3年HR 5.79(95%CI 3.11-10.78),5年HR 4.95(95%CI 2.88-8.51)。
- 无既往糖皮质激素使用BP患者全因死亡风险高于对照(HR 5.65,95%CI 4.19-7.61)。
核心结论
- 这项队列研究提示BP与约5倍的心血管疾病死亡风险相关,尤其在无高血压、无CVD史或无既往糖皮质激素或利尿剂使用患者中。
- 作者建议未来研究应探讨对BP患者CVD症状和体征进行常规监测和及时管理的获益。
研究设计与样本
- 在台湾中部一家三级医疗中心皮肤科门诊识别2007年1月1日至2017年12月31日诊断并治疗BP的患者,对照为无BP患者,按年龄、性别和皮肤科就诊日期4:1个体匹配。
- BP经病理确诊伴典型直接免疫荧光表现,或临床确诊伴典型临床表现、抗基底膜带抗体检测阳性且累计使用糖皮质激素至少28天。
- 共纳入252例BP患者和1008例匹配对照(N=1260),其中男性685例(54.4%),中位年龄78.0岁(IQR 70.3-84.8)。
- 死亡结局由国家死亡登记处确认,数据分析时间为2019年3月6日至2021年4月2日。
主要发现
- BP患者1年CVD死亡20例(7.9%)vs 对照13例(1.3%),3年28例(11.1%)vs 24例(2.4%),5年31例(12.3%)vs 39例(3.9%)。
- 校正潜在混杂后,BP患者1年CVD死亡HR 5.29(95%CI 2.40-11.68),3年HR 5.79(95%CI 3.11-10.78),5年HR 4.95(95%CI 2.88-8.51)。
- 亚组分析中,无高血压史患者BP相关CVD死亡HR 7.28(95%CI 3.87-13.69),无CVD史患者HR 6.59(95%CI 3.40-12.79),无既往利尿剂使用患者HR 5.75(95%CI 3.15-10.50)。
- 无既往糖皮质激素使用患者中,BP相关全因死亡风险高于对照(HR 5.65,95%CI 4.19-7.61)。
临床怎么用
- 作者建议未来研究应探讨对BP患者CVD症状和体征进行常规监测和及时管理的获益。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The role of bullous pemphigoid (BP) in cardiovascular disease (CVD) mortality remains controversial, and analyses of causes of death among patients with BP based on individual data remain lacking. OBJECTIVE: To evaluate the risk of all-cause mortality, CVD mortality, and cancer mortality in patients with BP. DESIGN, SETTING, AND PARTICIPANTS: This cohort study identified patients who received a diagnosis of and treatment for BP during their dermatology clinic visits at a tertiary medical center in central Taiwan between January 1, 2007, and December 31, 2017. Controls were patients without BP and were individually matched to cases (4:1) according to age, sex, and date of the dermatology clinic visit. Data were analyzed from March 6, 2019, to April 2, 2021. EXPOSURES: Bullous pemphigoid was confirmed pathologically with typical direct immunofluorescence findings or clinically with typical clinical presentation, positive findings of an anti-basement membrane zone antibody test, and corticosteroid use for at least 28 cumulative days. MAIN OUTCOMES AND MEASURES: Mortality outcomes confirmed by the National Death Registry. RESULTS: Of 252 patients with BP and 1008 matched control patients (N = 1260), 685 (54.4%) were men and the median age was 78.0 (IQR, 70.3-84.8) years. Patients with BP had higher CVD mortality at 1 year (20 [7.9%] vs 13 [1.3%]), 3 years (28 [11.1%] vs 24 [2.4%]), and 5 years (31 [12.3%] vs 39 [3.9%]) compared with matched control patients. After adjusting for potential confounding variables, patients with BP had a 5-fold higher risk of CVD mortality at 1 year (hazard ratio [HR], 5.29 [95% CI, 2.40-11.68]), 3 years (HR, 5.79 [95% CI, 3.11-10.78]), and 5 years (HR, 4.95 [95% CI, 2.88-8.51]). Subgroup analyses revealed that the CVD mortality risk associated with BP was higher in patients without a history of hypertension (HR, 7.28 [95% CI, 3.87-13.69]) or CVD (HR, 6.59 [95% CI, 3.40-12.79]) and in patients without prior diuretic use (HR, 5.75 [95% CI, 3.15-10.50]) compared with matched control patients. In addition, all-cause mortality associated with BP was higher in patients without prior corticosteroid use than in control patients (HR 5.65 [95% CI, 4.19-7.61]). CONCLUSIONS AND RELEVANCE: The findings of this cohort study suggest that BP was associated with a 5-fold higher risk of CVD mortality, particularly in patients without underlying hypertension or CVD or those without prior corticosteroid or diuretic use. Future studies should investigate the benefits of routine monitoring and timely management of CVD symptoms and signs in patients with BP.
引用
- Shen WC, Chiang HY, Chen PS, et al. Risk of All-Cause Mortality, Cardiovascular Disease Mortality, and Cancer Mortality in Patients With Bullous Pemphigoid. JAMA Dermatol. 2022. PMID: 34964804. doi:10.1001/jamadermatol.2021.5125
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。